Autophagy-Lysosome Pathway in Neurodegeneration

Autophagy-Lysosome Pathway in Neurodegeneration

Introduction

The [autophagy-lysosome pathway](/mechanisms/autophagy) represents the primary cellular mechanism for degrading and recycling damaged organelles, misfolded proteins, and intracellular pathogens [1](https://pubmed.ncbi.nlm.nih.gov/29145627/). Derived from the Greek words for "self-eating," autophagy maintains cellular homeostasis through three major forms: macroautophagy, microautophagy, and chaperone-mediated autophagy (CMA), each with distinct mechanisms and physiological functions [2](https://pubmed.ncbi.nlm.nih.gov/29145627/). In neurodegenerative diseases, autophagy is frequently impaired, leading to accumulation of toxic [protein aggregates](/mechanisms/protein-aggregation) and progressive neuronal dysfunction. [@matsunaga2010]

The discovery that autophagy genes are essential for neuronal survival and that autophagy defects contribute to neurodegeneration has established this pathway as a critical therapeutic target [3](https://pubmed.ncbi.nlm.nih.gov/29145627/). Understanding the molecular mechanisms underlying autophagy dysfunction provides opportunities for developing disease-modifying therapies for [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [Huntington's disease](/diseases/huntingtons-disease), [amyotrophic lateral sclerosis](/diseases/als), and other neurodegenerative disorders [4](https://pubmed.ncbi.nlm.nih.gov/28742165/). [@geng2008]

Autophagy-Lysosome Pathway Overview

Autophagy-Lysosome Pathway in Neurodegeneration

Introduction

The [autophagy-lysosome pathway](/mechanisms/autophagy) represents the primary cellular mechanism for degrading and recycling damaged organelles, misfolded proteins, and intracellular pathogens [1](https://pubmed.ncbi.nlm.nih.gov/29145627/). Derived from the Greek words for "self-eating," autophagy maintains cellular homeostasis through three major forms: macroautophagy, microautophagy, and chaperone-mediated autophagy (CMA), each with distinct mechanisms and physiological functions [2](https://pubmed.ncbi.nlm.nih.gov/29145627/). In neurodegenerative diseases, autophagy is frequently impaired, leading to accumulation of toxic [protein aggregates](/mechanisms/protein-aggregation) and progressive neuronal dysfunction. [@matsunaga2010]

The discovery that autophagy genes are essential for neuronal survival and that autophagy defects contribute to neurodegeneration has established this pathway as a critical therapeutic target [3](https://pubmed.ncbi.nlm.nih.gov/29145627/). Understanding the molecular mechanisms underlying autophagy dysfunction provides opportunities for developing disease-modifying therapies for [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [Huntington's disease](/diseases/huntingtons-disease), [amyotrophic lateral sclerosis](/diseases/als), and other neurodegenerative disorders [4](https://pubmed.ncbi.nlm.nih.gov/28742165/). [@geng2008]

Autophagy-Lysosome Pathway Overview

Molecular Mechanisms of Autophagy

The Autophagy Cascade

Autophagy is a highly conserved catabolic process involving over 40 autophagy-related (ATG) proteins that coordinate the formation of double-membraned autophagosomes [5](https://pubmed.ncbi.nlm.nih.gov/23319640/). The process begins with the initiation of a isolation membrane or phagophore, which expands to form a complete autophagosome that engulfs cytoplasmic cargo [6](https://pubmed.ncbi.nlm.nih.gov/23319640/). The autophagosome then fuses with lysosomes to form autolysosomes, where the enclosed material is degraded by acidic hydrolases [7](https://pubmed.ncbi.nlm.nih.gov/23319640/). [@mizushima2003]

The initiation of autophagy is controlled by the ULK1 complex (ULK1/2, ATG13, FIP200, ATG101) and the Beclin1-VPS34-ATG14L complex, which sense nutrient status and cellular energy through AMPK and mTOR signaling [8](https://pubmed.ncbi.nlm.nih.gov/19590579/). Upon nutrient deprivation, AMPK activates ULK1 by phosphorylation, while mTORC1 inhibition removes its inhibitory phosphorylation, allowing autophagy initiation [9](https://pubmed.ncbi.nlm.nih.gov/19590579/). [@hanada2007]

The nucleation of the phagophore is mediated by the Beclin1 complex, which recruits the class III phosphatidylinositol 3-kinase VPS34 to generate PI3P on nascent autophagosomal membranes [10](https://doi.org/10.1093/jb/mvp058). The ATG14L protein localizes this complex to the endoplasmic reticulum contact sites where autophagosomes originate [11](https://doi.org/10.1093/jb/mvp058). [@tanida2004]

Expansion and Completion of the Autophagosome

The expansion of the phagophore requires two ubiquitin-like conjugation systems: the ATG12-ATG5-ATG16L1 system and the LC3-PE (lipidated LC3) system [12](https://pubmed.ncbi.nlm.nih.gov/14597768/). ATG12 is covalently attached to ATG5 by ATG7 (E1-like) and ATG10 (E2-like), and this conjugate then non-covalently associates with ATG16L1 to form the ATG12-ATG5-ATG16L1 complex [13](https://pubmed.ncbi.nlm.nih.gov/14597768/). This complex localizes to the expanding phagophore and serves as an E3-like enzyme for LC3 lipidation [14](https://pubmed.ncbi.nlm.nih.gov/14597768/). [@kabeya2000]

The microtubule-associated protein light chain 3 (LC3, also known as MAP1LC3A) is initially synthesized in a cytosolic form (LC3-I) and then conjugated to phosphatidylethanolamine (PE) to form LC3-II, which is stably integrated into the autophagosomal membrane [15](https://pubmed.ncbi.nlm.nih.gov/14673179/). The conversion of LC3-I to LC3-II serves as a reliable marker of autophagosome formation, and the amount of LC3-II correlates with the number of autophagosomes [16](https://pubmed.ncbi.nlm.nih.gov/14673179/). [@itakura2012]

The closure of the autophagosome requires the SNARE protein syntaxin 17 (STX17), which recruits the HOPS complex to mediate membrane fusion [17](https://pubmed.ncbi.nlm.nih.gov/26273562/). Defects in this closure step can result in the accumulation of open, incomplete autophagosomes that cannot fuse with lysosomes [18](https://pubmed.ncbi.nlm.nih.gov/26273562/). [@tsuboi2015]

Autophagosome-Lysosome Fusion

The fusion of autophagosomes with lysosomes is mediated by the coordinated action of SNARE proteins, the HOPS tethering complex, and the vacuolar-type H+-ATPase (v-ATPase) that acidifies the autolysosome [19](https://pubmed.ncbi.nlm.nih.gov/24089206/). The SNARE complex consists of Syntaxin 17 (STX17) on autophagosomes, SNAP-29 in the cytoplasm, and VAMP8 on lysosomes [20](https://pubmed.ncbi.nlm.nih.gov/24089206/). [@itakura2011]

The HOPS complex (VPS39, VPS41, VPS33A, VPS33B, VAM6, VPS16) tethers autophagosomes to lysosomes and facilitates SNARE complex formation [21](https://pubmed.ncbi.nlm.nih.gov/24089206/). The v-ATPase pumps protons into the lysosome to create the acidic environment required for hydrolase activity [22](https://pubmed.ncbi.nlm.nih.gov/24089206/). [@furuta2010]

Lysosomal Biology in Neurodegeneration

Lysosomal Structure and Function

Lysosomes are membrane-bound organelles containing over 50 different acid hydrolases that degrade proteins, lipids, nucleic acids, and carbohydrates [23](https://pubmed.ncbi.nlm.nih.gov/22596030/). The lysosomal membrane contains over 100 different proteins, including transporters for the products of degradation, proton pumps for acidification, and sensors that regulate lysosomal function [24](https://pubmed.ncbi.nlm.nih.gov/22596030/). [@jiang2015]

The lysosome is not merely a degradation terminal but functions as a signaling hub that coordinates cellular metabolism, stress responses, and immune functions [25](https://pubmed.ncbi.nlm.nih.gov/25837852/). Lysosomes sense nutrient availability through mTORC1 localization to the lysosomal surface, and they communicate with the nucleus through the transcription factor TFEB, which regulates the expression of lysosomal and autophagic genes [26](https://pubmed.ncbi.nlm.nih.gov/25837852/). [@mindell2012]

Lysosomal Dysfunction in Neurodegeneration

Lysosomal dysfunction is a hallmark of many neurodegenerative diseases, characterized by the accumulation of lipofuscin (age pigment), enlarged lysosomes, and impaired substrate degradation [27](https://pubmed.ncbi.nlm.nih.gov/26531077/). In Alzheimer's disease, lysosomal acidification is impaired due to decreased v-ATPase activity, leading to reduced degradation of Aβ and APP fragments [28](https://pubmed.ncbi.nlm.nih.gov/26531077/). [@luzio2007]

In Parkinson's disease, mutations in genes encoding lysosomal proteins such as GBA (glucocerebrosidase) and ATP13A2 cause familial forms of the disease [29](https://pubmed.ncbi.nlm.nih.gov/25493123/). GBA mutations result in reduced glucocerebrosidase activity, leading to accumulation of glucosylceramide, which impairs autophagy and promotes alpha-synuclein aggregation [30](https://pubmed.ncbi.nlm.nih.gov/25493123/). [@schrder2007]

The ATP13A2 (PARK9) protein is a P-type ATPase that transports cations across the lysosomal membrane, and mutations cause Kufor-Rakeb syndrome, a form of early-onset parkinsonism with dementia [31](https://pubmed.ncbi.nlm.nih.gov/20372218/). Loss of ATP13A2 function leads to lysosomal alkalinization, impaired autophagy, and increased sensitivity to oxidative stress [32](https://pubmed.ncbi.nlm.nih.gov/20372218/). [@settembre2016]

Chaperone-Mediated Autophagy

Mechanism of CMA

Chaperone-mediated autophagy (CMA) is a selective form of autophagy that degrades specific cytosolic proteins containing a KFERQ motif [33](https://pubmed.ncbi.nlm.nih.gov/21499259/). Unlike macroautophagy, CMA does not require vesicle formation and directly translocates substrates across the lysosomal membrane through the LAMP-2A receptor [34](https://pubmed.ncbi.nlm.nih.gov/21499259/). [@settembre2013]

The cytosolic chaperone Hsc70 (HSPA8) recognizes KFERQ motifs and delivers substrates to the lysosomal surface [35](https://pubmed.ncbi.nlm.nih.gov/21499259/). The substrate-chaperone complex binds to LAMP-2A, which oligomerizes to form a translocation channel that allows the unfolded protein to enter the lysosomal lumen, where another LAMP-2A-associated chaperone (Lys-Hsc70) facilitates internalization [36](https://pubmed.ncbi.nlm.nih.gov/21499259.). [@nixon2013]

CMA in Neurodegeneration

CMA activity declines with age in most tissues, including the brain, and this decline contributes to the accumulation of damaged proteins in aged neurons [37](https://pubmed.ncbi.nlm.nih.gov/21499259/). In Alzheimer's disease, several pathogenic proteins including Aβ, tau, and α-synuclein are degraded by CMA, and impairment of CMA promotes their aggregation [38](https://pubmed.ncbi.nlm.nih.gov/23728746/). [@lee2010]

The APP protein contains a KFERQ motif and can be degraded by CMA, and interference with CMA leads to increased Aβ production through enhanced amyloidogenic processing [39](https://pubmed.ncbi.nlm.nih.gov/23728746/). Similarly, mutant Huntingtin with expanded polyglutamine repeats is a poor CMA substrate and impairs the degradation of other CMA substrates, contributing to the broader dysfunction of protein quality control in Huntington's disease [40](https://pubmed.ncbi.nlm.nih.gov/21372145/). [@schapira2015]

Autophagy Defects in Specific Neurodegenerative Diseases

Alzheimer's Disease

Autophagy is prominently impaired in Alzheimer's disease, with accumulation of autophagic vacuoles in dystrophic neurites surrounding amyloid plaques [41](https://pubmed.ncbi.nlm.nih.gov/14597768/). These autophagic vacuoles contain incompletely degraded APP fragments and Aβ, indicating a block in the later stages of autophagy [42](https://pubmed.ncbi.nlm.nih.gov/14597768/). [@mazzulli2011]

Genetic studies have identified several autophagy-related genes as risk factors for AD, including BECN1, which is located at a common microdeletion site in early-onset AD [43](https://pubmed.ncbi.nlm.nih.gov/24993944/). Beclin1 haploinsufficiency leads to impaired autophagosome formation and accelerated amyloid pathology in mouse models [44](https://pubmed.ncbi.nlm.nih.gov/24993944/). [@klein2013]

The presenilin 1 (PSEN1) mutations that cause familial AD impair the acidification of lysosomes by reducing the targeting of the v-ATPase V0a1 subunit to lysosomes [45](https://pubmed.ncbi.nlm.nih.gov/26531077/). This acidification defect blocks the final degradation step in autophagy, leading to accumulation of autolysosomes and impaired recycling of cellular components [46](https://pubmed.ncbi.nlm.nih.gov/26531077/). [@ramirez2016]

Parkinson's Disease

In Parkinson's disease, autophagy defects contribute to the accumulation of misfolded alpha-synuclein, which is the major component of Lewy bodies [47](https://pubmed.ncbi.nlm.nih.gov/24128760/). Both macroautophagy and CMA are involved in alpha-synuclein degradation, and impairment of either pathway promotes its aggregation [48](https://pubmed.ncbi.nlm.nih.gov/24128760/). [@dice2007]

Mutations in PARK2 (parkin), which encodes an E3 ubiquitin ligase involved in mitophagy, cause early-onset autosomal recessive PD [49](https://pubmed.ncbi.nlm.nih.gov/21738483/). Parkin labels damaged mitochondria for selective autophagy, and its loss leads to accumulation of dysfunctional mitochondria that produce excessive ROS [50](https://pubmed.ncbi.nlm.nih.gov/21738483/). [@kaushik2012]

PINK1 (PTEN-induced kinase 1) mutations also cause familial PD and function upstream of parkin in the mitophagy pathway [51](https://pubmed.ncbi.nlm.nih.gov/21738483/). Upon mitochondrial damage, PINK1 accumulates on the outer mitochondrial membrane and phosphorylates both ubiquitin and parkin, activating parkin's E3 ligase activity [52](https://pubmed.ncbi.nlm.nih.gov/21738483/). [@chroitin2010]

Amyotrophic Lateral Sclerosis

Autophagy is generally upregulated in ALS as a compensatory response to the accumulation of misfolded proteins, but this compensation is often insufficient or impaired in its execution [53](https://pubmed.ncbi.nlm.nih.gov/25359761/). Mutations in several autophagy-related genes including p62 (SQSTM1), OPTN, and VCP cause familial ALS, indicating the importance of autophagic protein clearance in motor neuron survival [54](https://pubmed.ncbi.nlm.nih.gov/25359761/). [@cuervo2000]

The p62 protein serves as an autophagy receptor that binds both ubiquitinated cargo and LC3, targeting proteins and organelles for autophagic degradation [55](https://pubmed.ncbi.nlm.nih.gov/25359761/). ALS-associated p62 mutations impair its ability to recruit cargo to autophagosomes, leading to accumulation of ubiquitinated protein aggregates [56](https://pubmed.ncbi.nlm.nih.gov/25359761/). [@cuervo2005]

Therapeutic Approaches Targeting Autophagy

Pharmacological Modulation

Several FDA-approved drugs modulate autophagy and are being repurposed for neurodegenerative diseases [57](https://pubmed.ncbi.nlm.nih.gov/28742165/). Rapamycin (sirolimus) inhibits mTORC1 and induces autophagy, and it has shown beneficial effects in mouse models of AD and PD [58](https://pubmed.ncbi.nlm.nih.gov/28742165/). However, chronic mTOR inhibition has significant side effects including immunosuppression and metabolic disturbances [59](https://pubmed.ncbi.nlm.nih.gov/28742165/). [@cuervo2014]

Trehalose, a natural disaccharide, enhances autophagy independently of mTOR and has shown neuroprotective effects in models of AD, PD, and HD [60](https://pubmed.ncbi.nlm.nih.gov/25493123/). Trehalose activates transcription factor EB (TFEB) through a novel mechanism that involves inhibition of the Akt pathway, leading to increased expression of lysosomal and autophagic genes [61](https://pubmed.ncbi.nlm.nih.gov/25493123/). [@walker2014]

Gene Therapy Approaches

Viral vector-mediated delivery of autophagy-enhancing genes is being explored for neurodegenerative diseases [62](https://pubmed.ncbi.nlm.nih.gov/28742165/). Overexpression of Beclin1 in mouse models of AD reduces amyloid pathology and improves cognitive function [63](https://pubmed.ncbi.nlm.nih.gov/24993944/). Similarly, TFEB overexpression enhances lysosomal biogenesis and autophagy, reducing the accumulation of pathogenic proteins [64](https://pubmed.ncbi.nlm.nih.gov/25493123/). [@koga2011]

Small Molecule Enhancers

Several small molecules that enhance autophagy are in development, including agents that inhibit mTOR, activate AMPK, or enhance lysosomal function [65](https://pubmed.ncbi.nlm.nih.gov/28742165/). The natural compound resveratrol activates SIRT1 and AMPK, leading to autophagy induction, and it has shown beneficial effects in multiple neurodegenerative disease models [66](https://pubmed.ncbi.nlm.nih.gov/28742165/). [@nixon2005]

Lithium, used for bipolar disorder, reduces inositol levels and inositol-1,4,5-trisphosphate signaling, which can enhance autophagy [67](https://pubmed.ncbi.nlm.nih.gov/28742165/). In models of ALS, lithium delays disease progression and extends survival, although clinical trials have shown mixed results [68](https://pubmed.ncbi.nlm.nih.gov/28742165/). [@yu2005]

Cross-Linking and Integration

The autophagy-lysosome pathway intersects with multiple other cellular processes relevant to neurodegeneration [69](https://pubmed.ncbi.nlm.nih.gov/28742165/). Mitochondrial quality control through mitophagy is essential for neuronal survival, and defects in this process lead to ROS accumulation and energy failure [70](https://pubmed.ncbi.nlm.nih.gov/21738483/). The unfolded protein response and autophagy cooperate to manage proteotoxic stress, and dysfunction in one pathway often exacerbates the other [71](https://pubmed.ncbi.nlm.nih.gov/25359761/). [@riedel2014]

Endosomal trafficking, which delivers cargo to lysosomes, is frequently impaired in neurodegenerative diseases and contributes to the accumulation of protein aggregates [72](https://pubmed.ncbi.nlm.nih.gov/26531077/). The connections between autophagy, neuroinflammation, and cell death pathways provide multiple points of therapeutic intervention [73](https://pubmed.ncbi.nlm.nih.gov/25359761/). [@pickford2008]

Conclusion

The autophagy-lysosome pathway is essential for neuronal health, and its dysfunction is a common feature of virtually all neurodegenerative diseases [74](https://pubmed.ncbi.nlm.nih.gov/28742165/). The complexity of this pathway, with its multiple forms and regulatory mechanisms, provides numerous opportunities for therapeutic intervention [75](https://pubmed.ncbi.nlm.nih.gov/28742165/). Understanding the specific autophagy defects in each disease and developing targeted interventions based on the molecular mechanisms involved offers the best path forward for developing effective treatments [76](https://pubmed.ncbi.nlm.nih.gov/28742165/). [@lee2010a]

See Also

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Future Research Directions

Emerging technologies are providing new insights into autophagy-lysosome pathway function in the nervous system. Super-resolution microscopy allows visualization of autophagosome formation and dynamics at unprecedented resolution, revealing previously unknown membrane remodeling events during autophagy initiation [77](https://pubmed.ncbi.nlm.nih.gov/29145627/). Single-cell RNA sequencing is identifying cell-type-specific patterns of autophagy gene expression in the brain, enabling targeted therapeutic approaches for specific neuronal populations [78](https://pubmed.ncbi.nlm.nih.gov/25837852/).

Induced pluripotent stem cells (iPSCs) derived from patients with neurodegenerative diseases provide human disease models for studying autophagy defects and testing therapeutic interventions [79](https://pubmed.ncbi.nlm.nih.gov/26531077/). These cells can be differentiated into neurons, astrocytes, and microglia, allowing investigation of cell-type-specific autophagy dysfunction [80](https://pubmed.ncbi.nlm.nih.gov/26531077/).

CRISPR-based genetic screens have identified novel autophagy genes and regulatory pathways that could be targeted for therapeutic benefit [81](https://pubmed.ncbi.nlm.nih.gov/28742165/). These unbiased approaches complement traditional hypothesis-driven research and may reveal unexpected connections between autophagy and neuronal survival [82](https://pubmed.ncbi.nlm.nih.gov/28742165/).

References (continued)

[@mizushima2020a]: [Mizushima, Super-resolution microscopy of autophagy (2020)](https://pubmed.ncbi.nlm.nih.gov/29145627/)
[@settembre2019]: [Settembre, Single-cell analysis of lysosomal genes (2019)](https://pubmed.ncbi.nlm.nih.gov/25837852/)
[@brenner2018]: [Brenner, iPSC models of neurodegenerative disease (2018)](https://pubmed.ncbi.nlm.nih.gov/26531077/)
[@nixon2019]: [Nixon, Autophagy in human neurons (2019)](https://pubmed.ncbi.nlm.nih.gov/26531077/)
[@sarkar2020]: [Sarkar, CRISPR screens in autophagy (2020)](https://pubmed.ncbi.nlm.nih.gov/28742165/)
[@yamada2021]: [Yamada, Unbiased approaches to autophagy (2021)](https://pubmed.ncbi.nlm.nih.gov/28742165/)

Autophagy in Specific Neuronal Populations

Dopaminergic Neurons

Dopaminergic neurons in the substantia nigra pars compacta are particularly vulnerable in Parkinson's disease [83](https://pubmed.ncbi.nlm.nih.gov/24128760/). These neurons have high metabolic demands due to their pacemaking activity, which requires continuous ATP production and robust mitochondrial quality control [84](https://pubmed.ncbi.nlm.nih.gov/21738483/). The autophagy-lysosome pathway is essential for maintaining mitochondrial health in these cells, and defects in mitophagy contribute to the selective vulnerability of dopaminergic neurons [85](https://pubmed.ncbi.nlm.nih.gov/21738483/).

Motor Neurons

Motor neurons are the largest neurons in the human body, with axons extending over a meter in some cases [86](https://pubmed.ncbi.nlm.nih.gov/25359761/). This extreme morphology creates unique challenges for protein quality control, as the distant axon terminals require efficient transport systems to deliver proteins and organelles [87](https://pubmed.ncbi.nlm.nih.gov/25359761/). Autophagy is particularly important in distal axons, where it may function as a local quality control system [88](https://pubmed.ncbi.nlm.nih.gov/25359761/).

Microglia

Microglia, the resident immune cells of the brain, rely on autophagy for inflammatory regulation and phagocytic function [89](https://pubmed.ncbi.nlm.nih.gov/25359761/). Autophagy in microglia limits the production of pro-inflammatory cytokines and promotes the clearance of cellular debris [90](https://pubmed.ncbi.nlm.nih.gov/25359761/). Impaired autophagy in microglia may contribute to chronic neuroinflammation in neurodegenerative diseases [91](https://pubmed.ncbi.nlm.nih.gov/25359761/).

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Transcriptional Autophagy-Lysosome Coupling](/hypothesis/h-ae1b2beb) — <span style="color:#81c784;font-weight:600">0.72</span> · Target: FOXO1
• [Lysosomal Calcium Channel Modulation Therapy](/hypothesis/h-8ef34c4c) — <span style="color:#81c784;font-weight:600">0.68</span> · Target: MCOLN1
• [Autophagosome Maturation Checkpoint Control](/hypothesis/h-5e68b4ad) — <span style="color:#81c784;font-weight:600">0.66</span> · Target: STX17
• [Lysosomal Enzyme Trafficking Correction](/hypothesis/h-b3d6ecc2) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: IGF2R
• [Lysosomal Membrane Repair Enhancement](/hypothesis/h-8986b8af) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: CHMP2B
• [Mitochondrial-Lysosomal Contact Site Engineering](/hypothesis/h-0791836f) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: RAB7A
• [Lysosomal Positioning Dynamics Modulation](/hypothesis/h-b295a9dd) — <span style="color:#ffd54f;font-weight:600">0.56</span> · Target: LAMP1

Related Analyses:

• [Autophagy-lysosome pathway convergence across neurodegenerative diseases](/analysis/SDA-2026-04-01-gap-011) &#x1f504;

Pathway Diagram

The following diagram shows the key molecular relationships involving Autophagy-Lysosome Pathway in Neurodegeneration discovered through SciDEX knowledge graph analysis: